| Identification | Back Directory | [Name]
Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate | [CAS]
120638-55-3 | [Synonyms]
Duract
Unii-8ecv571Y37
Bromfenac sodiu
Bromfenac ophthalmic
acetate hydrate(2:2:3)
BroMfenac sodiuM 1.5H2O
Bromfenac sodium hydrate
Sodium bromfenate hydrate
Bromfenac ophthalmic solution
Bromfenac Sodium Sesquihydrate
bromfenac sodium salt sesquihydrate
Sodium 2-(2-amino-3-(4-bromobenzoyl)
Bromfenac monosodium salt sesquihydrate
Bromfenac Sodium Sesquihydrate USP/EP/BP
Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate
Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate hydrate
Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate
Sodium 2-(2-amino-3-(4-bromobenzoyl)-phenyl)acetate trihydrate
2-AMino-3-(4-broMobenzoyl)benzeneacetic Acid SodiuM Salt Hydrate
Sodium 2-(2-amino-3-(4-bromobenzoyl)phenyl)acetate hydrate(2:2:3)
Benzeneacetic acid,2-amino-3-(4-bromobenzoyl)-,sodium salt,hydrate(2:2:3)
Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, hydrate (2:3) | [EINECS(EC#)]
695-342-6 | [Molecular Formula]
C15H11BrNNaO3 | [MDL Number]
MFCD23843787 | [MOL File]
120638-55-3.mol | [Molecular Weight]
356.15 |
| Chemical Properties | Back Directory | [Melting point ]
268-270°C (dec.) | [storage temp. ]
Refrigerator | [Uses]
Bromfenac (Xibrom, ISTA Pharmaceuticals, Irvine, USA; Bronuck, Senju Pharmaceutical, Osaka, Japan) is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients after undergoing cataract extraction. For this task, one drop of Xibrom may be applied to the affected eye twice daily beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period. The clinical safety and efficacy of bromfenac have been extensively studied in diverse comparative investigations, including the treatment of external or anterior ocular inflammatory diseases, allergic conjunctivitis, scleritis, and postoperative inflammation.The results of two phase III multicenter, randomized double-masked placebo-controlled clinical trials showed that bromfenac ophthalmic solution 0.09% was effective in the rapid resolution of ocular pain after cataract surgery, and there was a statistically significant difference between the bromfenac and placebo groups demonstrated in these phase III clinical trials. |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow Solid | [Definition]
ChEBI: The sesquihydrate of the sodium salt of bromfenac. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. | [Brand name]
Xibrom
(Ista). | [Description]
Duract was launched in the US as a potent, orally-active, long lasting peripheral
analgesic with antiinflammatory properties. It is structurally similar to ketoprofen and
diclofenac and can be prepared in three steps from 2-amino-4’-bromophenone using
Gassman’s oxindole synthesis. Duract’s biological effects are a result of its ability to
reduce prostaglandin production through inhibition of cyclooxygenase. As a 4-bromo
derivative of Amfenac, this modification increased the duration of analgesic activity
and antiinflammatory potency. It was also free of any CNS, cardiovascular or
autonomic effects. In comparison, 5 mg of Duract was equipotent to 650 mg of ASA
and 25 mg was slightly more potent than 400 mg of Ibuprofen. | [Originator]
American Home Products (US) |
|
|